BIOKAD, AO

🇷🇺Russia

Country: 🇷🇺Russia

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Study of the Safety, Pharmacodynamics and Efficacy of ANB-002 in Patients With Hemophilia B (SAFRAN)

Phase 1

Recruiting

Conditions: Hemophilia B

First Posted Date: 2023-11-07

Last Posted Date: 2025-06-13

Lead Sponsor: Biocad

Target Recruit Count: 28

Registration Number: NCT06120582

Locations: 🇧🇾
Republican Scientific and Practical Center for Radiation Medicine and Human Ecology, Gomel, Belarus
🇧🇾
Minsk Scientific and Practical Center for Surgery, Transplantology and Hematology, Minsk, Belarus
🇷🇺
State Autonomous Institution for Healthcare "Chelyabinsk Regional Clinical Hospital", Chelyabinsk, Russian Federation

and more 14 locations

A Clinical Study of the Pharmacokinetics and Safety of BCD-263 and Opdivo® as Monotherapy in Subjects With Advanced Melanoma of the Skin

Phase 1

Recruiting

Conditions: Advanced Melanoma

Interventions: Drug: BCD-263
Drug: Opdivo

First Posted Date: 2023-11-02

Last Posted Date: 2023-11-03

Lead Sponsor: Biocad

Target Recruit Count: 300

Registration Number: NCT06112808

Locations: 🇧🇾
Healthcare Institution "Minsk City Clinical Cancer Center", Minsk, Belarus
🇧🇾
State Institution "Republic Scientific and Practical Centre for Oncology and Medical Radiology Named after N.N.Aleksandrov", Minsk, Belarus
🇷🇺
Chelyabinsk Regional Clinical Center for Oncology and Nuclear Medicine, Chelyabinsk, Chelyabinsk Oblast, Russian Federation

and more 27 locations

Clinical Study of the Efficacy and Safety of BCD-201 and Keytruda in Subjects With Advanced Melanoma

Phase 3

Active, not recruiting

Conditions: Melanoma (Skin)

Interventions: Drug: BCD-201
Drug: Keytruda

First Posted Date: 2023-08-14

Last Posted Date: 2023-09-21

Lead Sponsor: Biocad

Target Recruit Count: 366

Registration Number: NCT05986331

Locations: 🇷🇺
Budgetary healthcare institution of the Omsk region "Clinical oncological dispensary", Omsk, Russian Federation
🇷🇺
"Saint Petersburg Clinical Research and Practice Center for Specialized Medical Care (Oncology)", Saint Petersburg, Russian Federation
🇷🇺
Federal State Budgetary Educational Institution of Higher Education "Saint Petersburg State University", Saint Petersburg, Russian Federation

A Study to Assess the PK, PD, Safety and Immunogenicity of Single IV Infusion of BCD-264 and Darzalex in Healthy Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BCD-264
Drug: Darzalex

First Posted Date: 2023-08-03

Last Posted Date: 2023-11-18

Lead Sponsor: Biocad

Target Recruit Count: 146

Registration Number: NCT05974969

Locations: 🇷🇺
Institute of the Human Brain n. a. N.P. Bekhtereva Russian Academy of Sciences, Saint Petersburg, Russian Federation
🇷🇺
Smorodintsev Research Institute of Influenza, Saint Petersburg, Russian Federation
🇷🇺
X7 Clinical Research, Saint Petersburg, Russian Federation

Clinical Study of the Efficacy and Safety of BCD-178 and Perjeta® as Neoadjuvant Therapy of HER2-Positive Breast Cancer

Phase 3

Recruiting

Conditions: Breast Cancer

Interventions: Drug: BCD-178
Drug: Perjeta

First Posted Date: 2023-04-06

Last Posted Date: 2023-09-21

Lead Sponsor: Biocad

Target Recruit Count: 374

Registration Number: NCT05802225

Locations: 🇷🇺
The Loginov Moscow Clinical Scientific Center MHD, Moscow, Russian Federation
🇷🇺
Budgetary healthcare institution of the Omsk region "Clinical oncological dispensary", Omsk, Russian Federation
🇷🇺
JSC "Modern Medical Technologies", Saint Petersburg, Russian Federation

A Two-Stage Study of the Efficacy, Safety, Pharmacokinetics, Pharmacodynamics and Immunogenicity of Various Doses of Levilimab When Administered Intravenously and Subcutaneously to Healthy Subjects and Subjects With Active Rheumatoid Arthritis

Phase 3

Active, not recruiting

Conditions: Rheumatoid Arthritis

Interventions: Drug: Levilimab

First Posted Date: 2023-04-05

Last Posted Date: 2023-04-05

Lead Sponsor: Biocad

Target Recruit Count: 261

Registration Number: NCT05800327

Locations: 🇷🇺
X7 Clinical Research, Saint Petersburg, Russian Federation

Prolgolimab 250 mg Q3W in Patients With Unresectable or Metastatic Melanoma

Phase 3

Active, not recruiting

Conditions: Unresectable or Metastatic Melanoma

Interventions: Drug: Prolgolimab

First Posted Date: 2023-03-24

Last Posted Date: 2023-03-24

Lead Sponsor: Biocad

Target Recruit Count: 114

Registration Number: NCT05783882

Locations: 🇷🇺
State Budgetary Institution of Healthcare of the Arkhangelsk Region "Arkhangelsk Regional Clinical Oncology Dispensary" (SBHI AR ARCOD), Arkhangel'sk, Russian Federation
🇷🇺
State Budgetary Institution of Healthcare "Clinical Oncology Dispensary of Chelyabinsk Region" (SBIH CODCR), Cheliabinsk, Russian Federation
🇷🇺
N.N. Blokhin Russian Cancer Research Center, Moscow, Russian Federation

and more 3 locations

Phase 1 Study of BCD-245 in Subjects With Neuroblastoma

Phase 1

Recruiting

Conditions: Neuroblastoma

First Posted Date: 2023-03-24

Last Posted Date: 2023-03-24

Lead Sponsor: Biocad

Target Recruit Count: 24

Registration Number: NCT05782959

Locations: 🇷🇺
Dmitry Rogachev National Medical Research Center Of Pediatric Hematology, Oncology and Immunology, Moscow, Russian Federation
🇷🇺
Russian Cancer Research Center named after N.N. Blokhin "of the Ministry of Health of the Russian Federation, Moscow, Russian Federation
🇷🇺
Raisa Gorbacheva Memorial Research Institute of Children Oncology, Hematology and Transplantation, Saint Petersburg, Russian Federation

A Study of Neoadjuvant Therapy With BCD-217 (Nurulimab + Prolgolimab) in Patients With Resectable Stage III Skin Melanoma

Phase 3

Recruiting

Conditions: Melanoma (Skin)
Melanoma Stage III

Interventions: Biological: BCD-217
Biological: anti-PD1
Procedure: Excision of the primary lesion
Procedure: Regional lymphadenectomy

First Posted Date: 2023-03-02

Last Posted Date: 2024-11-25

Lead Sponsor: Biocad

Target Recruit Count: 410

Registration Number: NCT05751928

Locations: 🇧🇾
State Institution "Republican Scientific and Practical Center of Oncology and Medical Radiology named after A.I. N.N. Alexandrov", Lesnoy, Belarus
🇧🇾
Healthcare Institution "Minsk City Clinical Cancer Center", Minsk, Belarus
🇧🇾
State Institution "Mogilev Regional Oncological Dispensary", Mogilev, Belarus

and more 33 locations

Study of the Safety and Efficacy of an Adeno-Associated Viral Vector Carrying the SMN Gene After a Single Intravenous Administration of Escalating Doses in Children With Spinal Muscular Atrophy (BLUEBELL)

Phase 1

Recruiting

Conditions: Spinal Muscular Atrophy (SMA)

First Posted Date: 2023-02-28

Last Posted Date: 2024-02-22

Lead Sponsor: Biocad

Target Recruit Count: 40

Registration Number: NCT05747261

Locations: 🇧🇾
1. State Institution Republican Scientific and Practical Center "Mother and Child", Minsk, Belarus
🇷🇺
State Autonomous Healthcare Institution of the Sverdlovsk Region "Regional Children's Clinical Hospital", Ekaterinburg, Russian Federation
🇷🇺
Federal State Autonomous Educational Institution of Higher Education "N.I. Pirogov Russian National Research Medical University", Ministry of Health of the Russian Federation, Moscow, Russian Federation

and more 3 locations

AI-Powered Research

Premium Access

BIOKAD, AO

Study of the Safety, Pharmacodynamics and Efficacy of ANB-002 in Patients With Hemophilia B (SAFRAN)

A Clinical Study of the Pharmacokinetics and Safety of BCD-263 and Opdivo® as Monotherapy in Subjects With Advanced Melanoma of the Skin

Clinical Study of the Efficacy and Safety of BCD-201 and Keytruda in Subjects With Advanced Melanoma

A Study to Assess the PK, PD, Safety and Immunogenicity of Single IV Infusion of BCD-264 and Darzalex in Healthy Subjects

Clinical Study of the Efficacy and Safety of BCD-178 and Perjeta® as Neoadjuvant Therapy of HER2-Positive Breast Cancer

A Two-Stage Study of the Efficacy, Safety, Pharmacokinetics, Pharmacodynamics and Immunogenicity of Various Doses of Levilimab When Administered Intravenously and Subcutaneously to Healthy Subjects and Subjects With Active Rheumatoid Arthritis

Prolgolimab 250 mg Q3W in Patients With Unresectable or Metastatic Melanoma

Phase 1 Study of BCD-245 in Subjects With Neuroblastoma

A Study of Neoadjuvant Therapy With BCD-217 (Nurulimab + Prolgolimab) in Patients With Resectable Stage III Skin Melanoma

Study of the Safety and Efficacy of an Adeno-Associated Viral Vector Carrying the SMN Gene After a Single Intravenous Administration of Escalating Doses in Children With Spinal Muscular Atrophy (BLUEBELL)